Automated HealthCare Solutions (AHCS) is Now AdvancedRx

Solidifying AdvancedRx's Top Position in the Pharmacy Services Market

TAMPA, Fla.--(BUSINESS WIRE)-- On February 2nd, 2024, Advanced Rx Management and Automated Healthcare Solutions (AHCS) officially came together as one, marking a significant milestone in the healthcare and pharmacy services industry. This exciting consolidation solidifies AdvancedRx's leading position in the pharmacy services market. The newly formed combined organization will operate under the AdvancedRx brand, leveraging the capabilities of the cutting-edge, ezDispense rules-based billing engine.

Dr. Gerald Glass, founder of Automated Healthcare Solutions, along with all minority shareholders have sold 100% of the ownership in AHCS to AdvancedRx. However, Dr. Glass will continue to own, maintain and develop the ezVerify business he established as a separate entity.

This transaction allows AdvancedRx to leverage AHCS's processes and cutting-edge technology to enhance its pharmacy services platform. AHCS historically boasted the industry's best collection rate, thanks to its innovative technology with ezDispense, efficient processes, and strong payor relationships. AdvancedRx, on the other hand, has a nationwide wholesale and retail pharmacy platform catering to all types of patient pharmaceutical needs across the country.

By combining the strengths of both companies, AdvancedRx, powered by ezDispense, now offers an even more comprehensive pharmacy solution for physicians, including in-office dispensing programs, nationwide mail-order pharmacies, and wholesale repackaged medications. The complete pharmacy services platform enables doctors to streamline their patients' medication processing, providing improved Patient Care for all patients' medication needs.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240222475770/en/

Liza Arruda
Phone: 954-809-9950
Email: [email protected]
https://advanced-rx.com/about-us

Source: AdvancedRx

You May Also Be Interested In

• Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
• NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
• Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and